Abstract

Aims

The study reports the relative and absolute risk of sudden cardiac death (SCD) in patients <36 years with prior myocardial infarction (MI).

Methods and results

Through review of death certificates, we identified all SCDs in Danes aged 18–35 years between 1 January 2000 until 31st December 2006. We then used the unique Danish civil registration number, which enabled us to follow all Danes in national registries, in the same period. Through the National Patient Registry we identified those with a prior myocardial infarction [implantable cardioverter defibrillator (ICD)-8: 410, ICD-10: I21 and I22] and incidence rates for SCD were estimated for survivors of MI and for individuals who had not yet suffered an MI, respectively. We estimated the relative risk of SCD and all-cause mortality by using extended Cox regression models. The 1 862 431 Danes aged between 18 and 35 years were followed in 9 388 453 person-years between 2000 and 2006. There were 7434 deaths of which 387 (5.2%) were SCDs. Myocardial infarction was diagnosed in 1234 patients, of those 10 died of SCD. Prior MI increased the incidence rate of SCD from 4.1 to 305.0 per 100 000 person-years [95% confidence interval (CI): 164.1–567.0]. Myocardial infarction was correlated with SCD and all-cause mortality, with a hazard ratio (HR) of 55.5 (95% CI: 29.5–104.4), P< 0.0001 and HR 8.3 (95% CI: 6.0–11.3), P< 0.0001, respectively.

Conclusion

We report that prior MI at a young age significantly increases SCD incidence from 4.1 to 305.0 per 100 000 person-years. Myocardial infarction is furthermore correlated with SCD and all-cause mortality with HR of 55.5 and 8.3, respectively.

Introduction

Loss of young family members due to a sudden cardiac death (SCD) is always a tragic event. In the past decades, studies have reported varying incidences and underlying causes of these deaths.1–7 In Danes below 36 years of age, ischaemic heart disease (IHD) remains the most common cardiac cause of SCD, although most cases are unexplained after autopsy.8 During the acute phase of myocardial infarction (MI), SCD is typically the result of acute ischaemia that provokes lethal ventricular arrhythmias. Later, the origin of arrhythmias evolves as a consequence of the structural remodelling of the left ventricle. Increasing mass and scars may cause re-entry circuits which eventually may lead to arrhythmias and SCD.9

In patients with prior MI and heart failure, the New York Heart Association class and the left ventricular ejection fraction (EF) are powerful predictors of SCD.10 In these patients at high risk, multiple clinical trials have demonstrated the effectiveness of the implantable cardioverter defibrillator (ICD) in reducing mortality.11–13 Nevertheless, although IHD markedly increases the risk of SCD, most patients suffering from SCD do not prior to their death fulfil criteria for prophylactic ICD implantation, and even with aggressive therapy, mortality remains high accounting for 50% in elderly patients.9,14–17 This is a major problem when designing preventive strategies and several other risk factors and tests have therefore been investigated.18–20

What's New?

• This is the first study that reports the relative and absolute risk of sudden cardiac death (SCD) in a nationwide setting, in young patients with prior myocardial infarction.

• In patients aged 18–35 years, prior myocardial infarction increases the incidence of SCD from 4.1 to 305.0 per 100 000 person-years (95% CI: 164.1–567.0).

• Myocardial infarction is correlated with SCD and all-cause mortality, with a hazard ratio (HR) of 55.5 (95% CI: 29.5–104.4), P< 0.0001 and HR 8.3 (95% CI: 6.0–11.3), P< 0.0001, respectively.

We have previously identified the highest possible incidence of SCD in the young in Denmark between 2000 and 2006 using both autopsied and non-autopsied cases.8 To our knowledge, no study has investigated prior MI as a risk factor of SCD in patients <36 years. By using the unique Danish registries we followed all Danes aged 18–36 years. We identified those diagnosed with prior MI and calculated their absolute and relative risk of later dying of SCD.

Methods

Danish registries and death certificates

All Danish citizens have a unique and personal civil registration number (CRN) which can be linked to national registries on an individual level. The Danish National Patient Registry (NPR) contains information on all in- and outpatient activities in Denmark since 1978. Diagnoses are coded according to the corresponding International Classification of Diseases, the 8th revision (ICD-8) until 1993 and since 1994 the 10th revision (ICD-10) has been used. In the Cause of Death Registry (CDR), all primary and contributing causes of death are recorded. In this way, all non-sudden cardiac causes of death were obtained and categorized. Data in the CDR are based on the death certificates that are always issued when death occurs inside the Danish borders.

The Danish death certificates can only be issued by a medical doctor. In cases where citizens or patients are found dead and/or the death is sudden and unexpected, medico-legal external examinations are mandatory by law. These thorough examinations are performed by 34 certified medical doctors together with the police, and information from these examinations can be found in the supplemental information field on the Danish death certificate. If no mode of death is secured by the medico-legal external examination a forensic autopsy is to be performed. Owing to this great level of detail, the Danish death certificates are highly suitable to identify SCDs in Denmark.8

Study population and sudden cardiac death

All Danes aged 18–35 years were followed through Danish registries. Individuals were observed from the day they turned 18 years or from 1 January 2000, whichever came last, until the day the individual turned 36 years or until 31 December 2006, whichever came first.

Our group has, through review of all death certificates and autopsy reports, identified all SCDs in this period (2000–2006), as previously described in detail by Winkel et al.8 Briefly, in that study we estimated the highest possible incidence of SCD by using both autopsied and non-autopsied cases. An SCD was in autopsied cases defined as ‘the sudden, natural unexpected death of unknown, or cardiac cause; in unwitnessed cases as a person last seen alive and functioning normally <24 h before being found dead and in witnessed cases as an acute change in cardiovascular status with the time to death being <1 h’. Based on the circumstances related to the death, the same criteria were used in the non-autopsied cases and a previous medical history was not an exclusion criterion, but was taken into account in every single case.

We use these previously defined cases from both autopsied and non-autopsied SCDs to calculate the incidences and relative risks in this study. Not all SCDs were autopsied, and we therefore preferred to use the term possible SCD (SCDpos).

Myocardial infarction, cardiovascular comorbidities, and study endpoint

We used the Danish NPR and searched our study population for patients with a discharge diagnosis of MI (ICD-8: 410 and ICD-10: I21 and I22). These ICD diagnoses have previously been validated with a positive predictive value of 92% and a sensitivity of 91% by Madsen et al.21 We excluded all deaths occurring in 2 weeks after an MI, thereby eliminating those dying from acute heart failure following MI. All SCDpos were furthermore characterized through the NPR with regard to cardiovascular comorbidities. Our study endpoint was defined as SCDpos or death from any other cause.

Hospital records and the general practitioner

For all SCDpos we were able to identify all previous hospital contacts through the NPR. We then retrieved all records when available to describe circumstances surrounding the related time, especially to the MI and later death. Finally, we contacted the general practitioners (GP) and retrieved their records to further describe comorbidities, dispositions, family history and medications, etc.

Statistical methods

Clinical features and endpoints of the analysis were assessed with the use of the Stata software package (StataCorp, Collage Station, TX, version 12.0). Incidence rates for SCDpos were estimated for survivors of MI and for individuals who had not yet suffered an MI, respectively. We estimated the relative risk of SCDpos and all-cause mortality by using extended Cox regression models. In the Cox model, MI was treated as a time-dependent Heaviside function, age was the underlying time-scale, and in the SCDpos model, individuals were censored in case of non-SCD. Individuals with MI at baseline were allowed to enter the analysis. Relevant model assumptions were found to be valid. Owing to the relatively low number of SCDpos among MI survivors, adjustment for potential confounders was not possible. We considered a two-sided P < 0.05 to be statistically significant. The study was approved by the local ethics committee (KF 01 272484), The Danish Data Protection Agency (2005-41-5237), and the Danish National Board of Health (7-505-29-58/1-5).

Results

In the seven-year study period 1862431 Danes aged between 18 and 36 years were followed in 9388453 person-years. Each individual was followed for a median of 6.4 years (IQR 3.1–7.0). There were 7 434 deaths of which 387 (5.2%) were SCDpos. Myocardial infarction was diagnosed in 1 234 patients, of those 434 patients (34%) had been diagnosed before entering the study period. The remaining 760 patients were diagnosed in between 2000 and 2006. Of 1 234 patients with prior MI, 86 died of non-SCD (Figure 1) and 10 died of SCDpos. Prior MI significantly increased the incidence rate of SCDpos from 4.1 to 305.0 per 100000 person-years (95% CI: 164.1–567.0) (Table 1). Myocardial infarction was correlated with SCDpos and all-cause mortality, with a hazard ratio (HR) of 55.5 (95% CI: 29.5–104.4), P< 0.0001 and HR 8.3 (95% CI: 6.0–11.3) P< 0.0001, respectively (Table 2).

Table 1

Incidences of sudden cardiac death in the young

Incidence of SCD per 100 000 person-years (95% CI)
Age 18–211.9 (1.3–2.8)
Age 21–242.1 (1.4–3.0)
Age 24–273.2 (2.4–4.2)
Age 27–304.4 (3.5–5.5)
Age 30–334.6 (3.7–5.7)
Age 33–357.6 (6.4–9.0)
No MI4.1 (3.7–4.6)
Prior MI305.0 (164.1–567.0)
Incidence of SCD per 100 000 person-years (95% CI)
Age 18–211.9 (1.3–2.8)
Age 21–242.1 (1.4–3.0)
Age 24–273.2 (2.4–4.2)
Age 27–304.4 (3.5–5.5)
Age 30–334.6 (3.7–5.7)
Age 33–357.6 (6.4–9.0)
No MI4.1 (3.7–4.6)
Prior MI305.0 (164.1–567.0)
Table 1

Incidences of sudden cardiac death in the young

Incidence of SCD per 100 000 person-years (95% CI)
Age 18–211.9 (1.3–2.8)
Age 21–242.1 (1.4–3.0)
Age 24–273.2 (2.4–4.2)
Age 27–304.4 (3.5–5.5)
Age 30–334.6 (3.7–5.7)
Age 33–357.6 (6.4–9.0)
No MI4.1 (3.7–4.6)
Prior MI305.0 (164.1–567.0)
Incidence of SCD per 100 000 person-years (95% CI)
Age 18–211.9 (1.3–2.8)
Age 21–242.1 (1.4–3.0)
Age 24–273.2 (2.4–4.2)
Age 27–304.4 (3.5–5.5)
Age 30–334.6 (3.7–5.7)
Age 33–357.6 (6.4–9.0)
No MI4.1 (3.7–4.6)
Prior MI305.0 (164.1–567.0)
Table 2

Hazard ratio for sudden cardiac death and all-cause mortality

HR for SCD (95% CI)P valueHR for all-cause mortality (95% CI)P value
Prior MI55.5 (29.5–104.4)<0.00018.3 (6.0–11.3)<0.0001
HR for SCD (95% CI)P valueHR for all-cause mortality (95% CI)P value
Prior MI55.5 (29.5–104.4)<0.00018.3 (6.0–11.3)<0.0001
Table 2

Hazard ratio for sudden cardiac death and all-cause mortality

HR for SCD (95% CI)P valueHR for all-cause mortality (95% CI)P value
Prior MI55.5 (29.5–104.4)<0.00018.3 (6.0–11.3)<0.0001
HR for SCD (95% CI)P valueHR for all-cause mortality (95% CI)P value
Prior MI55.5 (29.5–104.4)<0.00018.3 (6.0–11.3)<0.0001
Distribution of the causes of non-sudden deaths in persons with prior myocardial infarction aged 18–35 years in 2000–2006.
Figure 1

Distribution of the causes of non-sudden deaths in persons with prior myocardial infarction aged 18–35 years in 2000–2006.

The mean age at time of SCDpos was 31 years [standard deviation (SD)±2.7; range 26–34]. All patients except two were men and mean time from MI to death was 2.9 years (SD±3.0; range 58 days–11 years and 5 months). Known dispositions to IHD were active smoking (n= 8), family history of IHD (n= 5), hypercholesterolaemia (n= 3), and hypertension (n= 2).

The 10 SCDpos had previously, primarily been diagnosed with an ST-elevation-myocardial infarction (STEMI) treated with either thrombolysis or percutaneous transluminal coronary angioplasty. Ejection fraction after MI was estimated by echocardiography. All deaths happened at home or in public places except for one in-hospital death. Almost all patients died while awake and in four cases death occurred under physical activity/exercise. Of the seven witnessed deaths, six had bystander heart and lung resuscitation, five of those with documented malignant arrhythmias treated with defibrillation, although all unsuccessfully (Table 3).

Table 3

Patient characteristics

Patient numberPlace of MIPrimary MIEF after MIActivity at time of deathWitnessedAntecedenta symptomsProdromalb symptomsECGHLR
1HomeNon-STEMINo dataNo dataNoNoNoneNo
2Public placeMissed STEMI40%PhysicalYesAngina dyspneaNoVF/AsystoleYes—DC
3Public placeSTEMI35%PhysicalYesNoUnspecificVF/VTYes—DC
4HospitalNo dataNo dataAwake and relaxedYesNoNoVFYes—DC
5HomeSTEMI35%Awake and relaxedYesAnginaNoVF/VTYes—DC
6HomeSTEMI30%PhysicalYesNoUnspecificVFYes—DC
7HomeNo dataNo dataSleepNoFatigueNoneNo
8HomeSTEMI50%No dataYesNoNoVTYes—DC
9HomeSTEMIno dataNo dataYesAnginaAnginaNoneNo data
10Public placeSTEMI27%PhysicalYesNoNoAsystoleYes
Patient numberPlace of MIPrimary MIEF after MIActivity at time of deathWitnessedAntecedenta symptomsProdromalb symptomsECGHLR
1HomeNon-STEMINo dataNo dataNoNoNoneNo
2Public placeMissed STEMI40%PhysicalYesAngina dyspneaNoVF/AsystoleYes—DC
3Public placeSTEMI35%PhysicalYesNoUnspecificVF/VTYes—DC
4HospitalNo dataNo dataAwake and relaxedYesNoNoVFYes—DC
5HomeSTEMI35%Awake and relaxedYesAnginaNoVF/VTYes—DC
6HomeSTEMI30%PhysicalYesNoUnspecificVFYes—DC
7HomeNo dataNo dataSleepNoFatigueNoneNo
8HomeSTEMI50%No dataYesNoNoVTYes—DC
9HomeSTEMIno dataNo dataYesAnginaAnginaNoneNo data
10Public placeSTEMI27%PhysicalYesNoNoAsystoleYes

ECG, Electrocardiography; HLR, heart–lung resuscitation; VF, ventricular fibrillation; VT, ventricular tachycardia.

aAntecedent symptoms was defined as symptoms in the year to months leading up to the death.

bProdromal symptoms as symptoms in the minutes leading up to the death.

Table 3

Patient characteristics

Patient numberPlace of MIPrimary MIEF after MIActivity at time of deathWitnessedAntecedenta symptomsProdromalb symptomsECGHLR
1HomeNon-STEMINo dataNo dataNoNoNoneNo
2Public placeMissed STEMI40%PhysicalYesAngina dyspneaNoVF/AsystoleYes—DC
3Public placeSTEMI35%PhysicalYesNoUnspecificVF/VTYes—DC
4HospitalNo dataNo dataAwake and relaxedYesNoNoVFYes—DC
5HomeSTEMI35%Awake and relaxedYesAnginaNoVF/VTYes—DC
6HomeSTEMI30%PhysicalYesNoUnspecificVFYes—DC
7HomeNo dataNo dataSleepNoFatigueNoneNo
8HomeSTEMI50%No dataYesNoNoVTYes—DC
9HomeSTEMIno dataNo dataYesAnginaAnginaNoneNo data
10Public placeSTEMI27%PhysicalYesNoNoAsystoleYes
Patient numberPlace of MIPrimary MIEF after MIActivity at time of deathWitnessedAntecedenta symptomsProdromalb symptomsECGHLR
1HomeNon-STEMINo dataNo dataNoNoNoneNo
2Public placeMissed STEMI40%PhysicalYesAngina dyspneaNoVF/AsystoleYes—DC
3Public placeSTEMI35%PhysicalYesNoUnspecificVF/VTYes—DC
4HospitalNo dataNo dataAwake and relaxedYesNoNoVFYes—DC
5HomeSTEMI35%Awake and relaxedYesAnginaNoVF/VTYes—DC
6HomeSTEMI30%PhysicalYesNoUnspecificVFYes—DC
7HomeNo dataNo dataSleepNoFatigueNoneNo
8HomeSTEMI50%No dataYesNoNoVTYes—DC
9HomeSTEMIno dataNo dataYesAnginaAnginaNoneNo data
10Public placeSTEMI27%PhysicalYesNoNoAsystoleYes

ECG, Electrocardiography; HLR, heart–lung resuscitation; VF, ventricular fibrillation; VT, ventricular tachycardia.

aAntecedent symptoms was defined as symptoms in the year to months leading up to the death.

bProdromal symptoms as symptoms in the minutes leading up to the death.

To describe comorbidity all ICD-8/10 diagnoses from the NPR along with medications are presented. Two patients had known insulin-dependent diabetes mellitus, one had epilepsy diagnosed before MI and finally one patient had a congenital heart disease. The remaining six patients had no other comorbidities than MI prior to their death (Table 4).

Table 4

Recorded diagnoses from the National Patient Registry and medication

Patient numberICD-8/10DateDescriptionMedication before death
1E10.920-01-95Insulin-dependent diabetes without complications- Mixtard
I21.931-01-97Acute myocardial infarction, unspecified- Acetylsalicylic acid
E10.618-09-98Insulin-dependent diabetes with other specified complications- Metoprolol
E15.907-10-98Hypoglycaemic coma- Verapamil
2I21.925-01-03Acute myocardial infarction, unspecified- Furosemid
I20.929-01-03Angina pectoris, unspecified
  • - Potassium chloride

  • - Clopidogrel

  • - Metoprolol

  • - Esomeprazole

 
3I21.912-08-04Acute myocardial infarction, unspecified- No data
47473931-01-78Atresia, stenosis congenital arteriae pulmonalis- Digoxin
7463918-02-78Defectus congenitus septi ventriculorum- Acetylsalicylic acid
7460905-02-81Truncus communis
4270918-11-88Incompensatio cordis
7465925-12-88Ostium atrioventriculare commune
4210904-12-91Endocarditis acuta et subacuta bacterialis
Q20.013-02-95Common arterial trunk
I21.910-08-99Acute myocardial infarction, unspecified
5I21.005-10-03Acute transmural myocardial infarction of anterior wall- Acetylsalicylic acid
I25.917-04-05Chronic ischaemic heart disease, unspeicified
  • - Clopidogrel

  • - Warfarin

  • - Atorvastatin

  • - Perindopril

  • - Metoprolol

 
6I21.907-10-01Acute myocardial infarction, unspecified
  • - Warfarin

  • - Metoprolol

  • - Acetylsalicylic acid

  • - Pravastatin

  • - Ramipril

 
7R56.817-02-94Other and unspecified convulsions- Methadon
G41.001-06-95Grand mal status epilepticus
I21.103-12-97Acute transmural myocardial infarction of inferior wall
G40.927-10-98Epilepsy, unspecified
G40.305-11-98Generalized idiopathic epilepsy and epileptic syndromes
82500903-12-84Diabetes mellitus, insulino independente- Insulin detemir
2500720-03-85Coma diabeticum, insulin independente- Insulin (humant)
E10.228-01-96Diabetes with renal complications- Candesartan cilexetil
E10.502-08-04Diabetes with circulatory complications- Acetylsalicylic acid
E10.708-12-04Diabetes with multiple complication- Simvastatin
H36.008-06-04Diabetic retinopathy
I21.303-08-04Acute transmural myocardial infarction of unspecified site
H43.109-12-04Vitreous haemorrhage
E16.021-02-05Drug-induced hypoglycaemia without coma
9I21.313-06-06Acute transmural myocardial infarction of unspecified site- Risperidone
E16.013-06-06Drug-induced hypoglycaemia without coma
  • - Chlorprothixen

  • - Zopiclone

  • - Clonazepam

  • - Citalopram

  • - Clopidogrel

  • - Acetylsalicylic acid

 
104109918-03-92Infartus myocardii acutus (hypertens.arterial.non indic)- Warfarin
I20.901-01-96Angina pectoris, unspecified
  • - Perindopril

  • - Acetylsalicylic acid

 
Patient numberICD-8/10DateDescriptionMedication before death
1E10.920-01-95Insulin-dependent diabetes without complications- Mixtard
I21.931-01-97Acute myocardial infarction, unspecified- Acetylsalicylic acid
E10.618-09-98Insulin-dependent diabetes with other specified complications- Metoprolol
E15.907-10-98Hypoglycaemic coma- Verapamil
2I21.925-01-03Acute myocardial infarction, unspecified- Furosemid
I20.929-01-03Angina pectoris, unspecified
  • - Potassium chloride

  • - Clopidogrel

  • - Metoprolol

  • - Esomeprazole

 
3I21.912-08-04Acute myocardial infarction, unspecified- No data
47473931-01-78Atresia, stenosis congenital arteriae pulmonalis- Digoxin
7463918-02-78Defectus congenitus septi ventriculorum- Acetylsalicylic acid
7460905-02-81Truncus communis
4270918-11-88Incompensatio cordis
7465925-12-88Ostium atrioventriculare commune
4210904-12-91Endocarditis acuta et subacuta bacterialis
Q20.013-02-95Common arterial trunk
I21.910-08-99Acute myocardial infarction, unspecified
5I21.005-10-03Acute transmural myocardial infarction of anterior wall- Acetylsalicylic acid
I25.917-04-05Chronic ischaemic heart disease, unspeicified
  • - Clopidogrel

  • - Warfarin

  • - Atorvastatin

  • - Perindopril

  • - Metoprolol

 
6I21.907-10-01Acute myocardial infarction, unspecified
  • - Warfarin

  • - Metoprolol

  • - Acetylsalicylic acid

  • - Pravastatin

  • - Ramipril

 
7R56.817-02-94Other and unspecified convulsions- Methadon
G41.001-06-95Grand mal status epilepticus
I21.103-12-97Acute transmural myocardial infarction of inferior wall
G40.927-10-98Epilepsy, unspecified
G40.305-11-98Generalized idiopathic epilepsy and epileptic syndromes
82500903-12-84Diabetes mellitus, insulino independente- Insulin detemir
2500720-03-85Coma diabeticum, insulin independente- Insulin (humant)
E10.228-01-96Diabetes with renal complications- Candesartan cilexetil
E10.502-08-04Diabetes with circulatory complications- Acetylsalicylic acid
E10.708-12-04Diabetes with multiple complication- Simvastatin
H36.008-06-04Diabetic retinopathy
I21.303-08-04Acute transmural myocardial infarction of unspecified site
H43.109-12-04Vitreous haemorrhage
E16.021-02-05Drug-induced hypoglycaemia without coma
9I21.313-06-06Acute transmural myocardial infarction of unspecified site- Risperidone
E16.013-06-06Drug-induced hypoglycaemia without coma
  • - Chlorprothixen

  • - Zopiclone

  • - Clonazepam

  • - Citalopram

  • - Clopidogrel

  • - Acetylsalicylic acid

 
104109918-03-92Infartus myocardii acutus (hypertens.arterial.non indic)- Warfarin
I20.901-01-96Angina pectoris, unspecified
  • - Perindopril

  • - Acetylsalicylic acid

 
Table 4

Recorded diagnoses from the National Patient Registry and medication

Patient numberICD-8/10DateDescriptionMedication before death
1E10.920-01-95Insulin-dependent diabetes without complications- Mixtard
I21.931-01-97Acute myocardial infarction, unspecified- Acetylsalicylic acid
E10.618-09-98Insulin-dependent diabetes with other specified complications- Metoprolol
E15.907-10-98Hypoglycaemic coma- Verapamil
2I21.925-01-03Acute myocardial infarction, unspecified- Furosemid
I20.929-01-03Angina pectoris, unspecified
  • - Potassium chloride

  • - Clopidogrel

  • - Metoprolol

  • - Esomeprazole

 
3I21.912-08-04Acute myocardial infarction, unspecified- No data
47473931-01-78Atresia, stenosis congenital arteriae pulmonalis- Digoxin
7463918-02-78Defectus congenitus septi ventriculorum- Acetylsalicylic acid
7460905-02-81Truncus communis
4270918-11-88Incompensatio cordis
7465925-12-88Ostium atrioventriculare commune
4210904-12-91Endocarditis acuta et subacuta bacterialis
Q20.013-02-95Common arterial trunk
I21.910-08-99Acute myocardial infarction, unspecified
5I21.005-10-03Acute transmural myocardial infarction of anterior wall- Acetylsalicylic acid
I25.917-04-05Chronic ischaemic heart disease, unspeicified
  • - Clopidogrel

  • - Warfarin

  • - Atorvastatin

  • - Perindopril

  • - Metoprolol

 
6I21.907-10-01Acute myocardial infarction, unspecified
  • - Warfarin

  • - Metoprolol

  • - Acetylsalicylic acid

  • - Pravastatin

  • - Ramipril

 
7R56.817-02-94Other and unspecified convulsions- Methadon
G41.001-06-95Grand mal status epilepticus
I21.103-12-97Acute transmural myocardial infarction of inferior wall
G40.927-10-98Epilepsy, unspecified
G40.305-11-98Generalized idiopathic epilepsy and epileptic syndromes
82500903-12-84Diabetes mellitus, insulino independente- Insulin detemir
2500720-03-85Coma diabeticum, insulin independente- Insulin (humant)
E10.228-01-96Diabetes with renal complications- Candesartan cilexetil
E10.502-08-04Diabetes with circulatory complications- Acetylsalicylic acid
E10.708-12-04Diabetes with multiple complication- Simvastatin
H36.008-06-04Diabetic retinopathy
I21.303-08-04Acute transmural myocardial infarction of unspecified site
H43.109-12-04Vitreous haemorrhage
E16.021-02-05Drug-induced hypoglycaemia without coma
9I21.313-06-06Acute transmural myocardial infarction of unspecified site- Risperidone
E16.013-06-06Drug-induced hypoglycaemia without coma
  • - Chlorprothixen

  • - Zopiclone

  • - Clonazepam

  • - Citalopram

  • - Clopidogrel

  • - Acetylsalicylic acid

 
104109918-03-92Infartus myocardii acutus (hypertens.arterial.non indic)- Warfarin
I20.901-01-96Angina pectoris, unspecified
  • - Perindopril

  • - Acetylsalicylic acid

 
Patient numberICD-8/10DateDescriptionMedication before death
1E10.920-01-95Insulin-dependent diabetes without complications- Mixtard
I21.931-01-97Acute myocardial infarction, unspecified- Acetylsalicylic acid
E10.618-09-98Insulin-dependent diabetes with other specified complications- Metoprolol
E15.907-10-98Hypoglycaemic coma- Verapamil
2I21.925-01-03Acute myocardial infarction, unspecified- Furosemid
I20.929-01-03Angina pectoris, unspecified
  • - Potassium chloride

  • - Clopidogrel

  • - Metoprolol

  • - Esomeprazole

 
3I21.912-08-04Acute myocardial infarction, unspecified- No data
47473931-01-78Atresia, stenosis congenital arteriae pulmonalis- Digoxin
7463918-02-78Defectus congenitus septi ventriculorum- Acetylsalicylic acid
7460905-02-81Truncus communis
4270918-11-88Incompensatio cordis
7465925-12-88Ostium atrioventriculare commune
4210904-12-91Endocarditis acuta et subacuta bacterialis
Q20.013-02-95Common arterial trunk
I21.910-08-99Acute myocardial infarction, unspecified
5I21.005-10-03Acute transmural myocardial infarction of anterior wall- Acetylsalicylic acid
I25.917-04-05Chronic ischaemic heart disease, unspeicified
  • - Clopidogrel

  • - Warfarin

  • - Atorvastatin

  • - Perindopril

  • - Metoprolol

 
6I21.907-10-01Acute myocardial infarction, unspecified
  • - Warfarin

  • - Metoprolol

  • - Acetylsalicylic acid

  • - Pravastatin

  • - Ramipril

 
7R56.817-02-94Other and unspecified convulsions- Methadon
G41.001-06-95Grand mal status epilepticus
I21.103-12-97Acute transmural myocardial infarction of inferior wall
G40.927-10-98Epilepsy, unspecified
G40.305-11-98Generalized idiopathic epilepsy and epileptic syndromes
82500903-12-84Diabetes mellitus, insulino independente- Insulin detemir
2500720-03-85Coma diabeticum, insulin independente- Insulin (humant)
E10.228-01-96Diabetes with renal complications- Candesartan cilexetil
E10.502-08-04Diabetes with circulatory complications- Acetylsalicylic acid
E10.708-12-04Diabetes with multiple complication- Simvastatin
H36.008-06-04Diabetic retinopathy
I21.303-08-04Acute transmural myocardial infarction of unspecified site
H43.109-12-04Vitreous haemorrhage
E16.021-02-05Drug-induced hypoglycaemia without coma
9I21.313-06-06Acute transmural myocardial infarction of unspecified site- Risperidone
E16.013-06-06Drug-induced hypoglycaemia without coma
  • - Chlorprothixen

  • - Zopiclone

  • - Clonazepam

  • - Citalopram

  • - Clopidogrel

  • - Acetylsalicylic acid

 
104109918-03-92Infartus myocardii acutus (hypertens.arterial.non indic)- Warfarin
I20.901-01-96Angina pectoris, unspecified
  • - Perindopril

  • - Acetylsalicylic acid

 

Surprisingly, none of these 10 deaths were autopsied and only 3 patients had a medico-legal external examination performed.

Discussion

In this nationwide study we followed all Danes aged 18–36 years for a 7-year period through registries, from 2000 to 2006. We identified 1862431 persons and followed them for 9388453 person-years with an incidence of SCDpos of 4.1 per 100 000 person-years. Despite the young age of our study population, 1234 patients had an MI discharge diagnosis in the NPR and of those, 474 (38%), were diagnosed before 1 January 2000. Prior MI significantly increased the incidence rate of SCDpos from 4.1 to 305.0 per 100000 person-years.

This study is not the first to describe an association between IHD and SCD,22 although previously studies to our knowledge all have been conducted on much older populations. Thus, in patients with IHD there has been reported a 2.8- to 5.3-fold increase in risk of SCD,23 and women and men with prior MI have been associated with a 4- to 10-fold higher risk of SCD, respectively.24,25 We reported an HR of 55.5 for SCDpos after MI and hence, MI seems to have a much higher impact in the young compared with older populations.

Although we find an HR of 55.5, the absolute risk of av SCDpos still remains low. It is noteworthy, though, that this study does not address all deaths related to MI and IHD. We only included patients if MI was diagnosed more than 2 weeks before death thereby excluding all those dying from acute heart failure following MI. In fact, IHD is the most common cardiac cause of SCD in young Danes, although most cases are unexplained. Of 314 previously reported cases of SCD in 2000–2006 in persons aged 1–35 years, 40 SCD cases were caused by IHD, and of those 39 were aged between 18 and 36 years. None of these specific patients had a history of prior MI.8

The shortest interval between MI and SCDpos was almost 2 months and the mean time from MI to death was 2.9 years. It is well-known that in older populations, mortality rates are highest in the first 30 days after MI, and from here gradually decreases over time.26,27 Therefore it seems that survival patterns might look different in the young, and it could be speculated that with a longer follow-up period, even more patients would die of SCDpos following MI.

Improvements in primary and secondary prevention have, in the past 30 years, caused a decline in mortality due to IHD,28 but SCD mortality has declined to a lesser extent.29 Hence, new prevention strategies that will reduce SCD mortality are today a major challenge to reduce the overall mortality. Once overt IHD has been established traditionally risk factors for IHD are not specific for prediction of SCD with the exception of diabetes,22 kidney disease,22,30 and smoking.31 The current best-known predictor is heart failure with reduced EF, but most patients do not have a documented EF < 35% prior to their death32 and this may especially be a problem in the young. We found only two individuals fulfilling these criteria and they were both physically active at the time of death, which may indicate that they did not suffer from severe heart failure at all.

Furthermore, it is obvious that even though we report a high relative risk, the absolute risk is low and implantation of ICD-units in all young patients with MI in general is not an option, and better stratifications tools are therefore needed.

Sudden and unexpected deaths are by Danish laws required to have medico-legal external examinations together with the police, but only three persons were examined. It is remarkable and problematic that none of these patients were autopsied considering that 6 of 10 patients had no other known comorbidities than prior MI. Because none of these patients were autopsied we could not tell for sure if all patients died of SCD, hence we used the term SCDpos. Nevertheless, all patients had a prior MI, and because we had access to their death certificate, registry entries, and records from both hospitals and GPs we indeed believe that they definitely died of SCD, although not documented by autopsy.

In conclusion we found 1234 patients previously diagnosed with MI aged 18–35 years, of which 10 patients died of SCDpos. Although seemingly few deaths were found, the incidence of SCDpos increased significantly from 4.1 to 305.0 per 100,000 person-years in patients diagnosed with prior MI. We furthermore report that in a young population, MI indeed increases risk of SCDpos and all-cause with HR of 55.5 and 8.3, respectively. In the future, studies should evaluate the long-term consequences of MI in a young age, and focus on improving the preventive strategies, so that we will reduce the burden of SCD in not only the young but also in general.

Study strengths and limitations

The main strength of this study was that it was performed on nationwide data from a thorough review of death certificates of all deaths between 1 January 2000 and 31 December 2006. The Danish death certificates are unique and suitable to identify SCDs. It is, though, a limitation that they were identified in a retrospective design. It was fairly easy to extract data on whether or not a death was witnessed and if seen alive <24 h before, but in some cases more precise time limits were difficult to assess (<1 h). If in doubt the cases were discarded. Furthermore, it is a major limitation that none of our cases were autopsied thereby securing the SCD diagnosis, but they all fulfilled previously defined criteria for SCD.8 Myocardial infarction diagnoses were retrieved through nationwide registries which have previously been validated with a positive predictive value of 92% and a sensitivity of 91%.21 Owing to relatively few numbers of SCD after MI, the study had insufficient statistical power to adjust for confounders. Furthermore, we cannot exclude that an arrhythmic event may have occurred in these 10 patients without being directly associated with the primary MI. We allowed patients to enter the analysis if MI were diagnosed before 1 January 2000, thereby introducing some survivor bias. Nevertheless, to meet such problems with bias and confounding, a prospective design would necessitate an enormous cohort due to the few MIs and SCDs in this young population and this is currently the best that can be done.

Author contributions

Bjarke Risgaard: drafting of manuscript, statistics, data collection, data analysis, and review of death certificates.

Jonas Bille Nielsen: statistics, drafting of manuscript.

Reza Jabbari: critical revision of manuscript and data analysis.

Stig Haunsø: fundraising and critical revision of manuscript.

Anders Gaarsdal Holst: study design, statistics, review of death certificates.

Bo Gregers Winkel: review of death certificates, critical revision manuscript, and study design.

Jacob Tfelt-Hansen: review of death certificates, critical revision manuscript, and study design.

Acknowledgements

The work was supported by The Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC), The John and Birthe Meyer Foundation, The Research Foundation at the Heart Centre, Rigshopitalet, and the foundation of Edith and Henrik Henriksens mindelegat [50892].

Conflict of interest: none declared.

References

1
Doolan
A
Langlois
N
Semsarian
C
,
Causes of sudden cardiac death in young Australians
Med J Aust
,
2004
, vol.
180
(pg.
110
-
2
)
2
Wisten
A
Forsberg
H
Krantz
P
Messner
T
,
Sudden cardiac death in 15–35-year olds in Sweden during 1992–99
J Intern Med
,
2002
, vol.
252
(pg.
529
-
36
)
3
Vaartjes
I
Hendrix
A
Hertogh
EM
Grobbee
DE
Doevendans
PA
Mosterd
A
et al.
,
Sudden death in persons younger than 40 years of age: incidence and causes
Eur J Cardiovasc Prev Rehabil
,
2009
, vol.
16
(pg.
592
-
6
)
4
Puranik
R
Chow
CK
Duflou
JA
Kilborn
MJ
McGuire
MA
,
Sudden death in the young
Heart Rhythm
,
2005
, vol.
2
(pg.
1277
-
82
)
5
Morentin
B
Suárez-Mier
MP
Aguilera
B
,
Sudden unexplained death among persons 1–35 years old
Forensic Sci Int
,
2003
, vol.
135
(pg.
213
-
7
)
6
Quigley
F
Greene
M
O'Connor
D
Kelly
F
,
A survey of the causes of sudden cardiac death in the under 35-year-age group
Ir Med J
,
2005
, vol.
98
(pg.
232
-
5
)
7
Morris
VB
Keelan
T
Leen
E
Keating
J
Magee
H
O'Neill
JO
et al.
,
Sudden cardiac death in the young: a 1-year post-mortem analysis in the Republic of Ireland
Ir J Med Sci
,
2009
, vol.
178
(pg.
257
-
61
)
8
Winkel
BG
Holst
AG
Theilade
J
Kristensen
IB
Thomsen
JL
Ottesen
GL
et al.
,
Nationwide study of sudden cardiac death in persons aged 1–35 years
Eur Heart J
,
2011
, vol.
32
(pg.
983
-
90
)
9
Bunch
TJ
Hohnloser
SH
Gersh
BJ
,
Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators
Circulation
,
2007
, vol.
115
(pg.
2451
-
7
)
10
Buxton
AE
,
Risk stratification for sudden death in patients with coronary artery disease
Heart Rhythm
,
2009
, vol.
6
(pg.
836
-
47
)
11
Buxton
AE
Lee
KL
Fisher
JD
Josephson
ME
Prystowsky
EN
Hafley
G
,
A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators
N Engl J Med
,
1999
, vol.
341
(pg.
1882
-
90
)
12
Moss
AJ
Hall
WJ
Cannom
DS
Daubert
JP
Higgins
SL
Klein
H
et al.
,
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators
N Engl J Med
,
1996
, vol.
335
(pg.
1933
-
40
)
13
Moss
AJ
Zareba
W
Hall
WJ
Klein
H
Wilber
DJ
Cannom
DS
et al.
,
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
N Engl J Med
,
2002
, vol.
346
(pg.
877
-
83
)
14
Zipes
DP
Wellens
HJ
,
Sudden cardiac death
Circulation
,
1998
, vol.
98
(pg.
2334
-
51
)
15
Pouleur
A-C
Barkoudah
E
Uno
H
Skali
H
Finn
PV
Zelenkofske
SL
et al.
,
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
Circulation
,
2010
, vol.
122
(pg.
597
-
602
)
16
Scirica
BM
Braunwald
E
Belardinelli
L
Hedgepeth
CM
Spinar
J
Wang
W
et al.
,
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial
Circulation
,
2010
, vol.
122
(pg.
455
-
62
)
17
Harkness
JR
Morrow
DA
Braunwald
E
Ren
F
Lopez-Sendon
J
Bode
C
et al.
,
Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial)
Am J Cardiol
,
2011
, vol.
108
(pg.
1373
-
81
)
18
Chugh
SS
,
Early identification of risk factors for sudden cardiac death
Nat Rev Cardiol
,
2010
, vol.
7
(pg.
318
-
26
)
19
Liew
R
,
Prediction of sudden arrhythmic death following acute myocardial infarction
Heart
,
2010
, vol.
96
(pg.
1086
-
94
)
20
Stecker
EC
Chugh
SS
,
Prediction of sudden cardiac death: next steps in pursuit of effective methodology
J Interv Card Electrophysiol
,
2011
, vol.
31
(pg.
101
-
7
)
21
Madsen
M
Davidsen
M
Rasmussen
S
Abildstrom
SZ
Osler
M
,
The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry
J Clin Epidemiol
,
2003
, vol.
56
(pg.
124
-
30
)
22
Deo
R
Vittinghoff
E
Lin
F
Tseng
ZH
Hulley
SB
Shlipak
MG
,
Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease
Arch Intern Med
,
2011
, vol.
171
(pg.
1703
-
9
)
23
Kannel
WB
Cupples
LA
D'Agostino
RB
,
Sudden death risk in overt coronary heart disease: the Framingham Study
Am Heart J
,
1987
, vol.
113
(pg.
799
-
804
)
24
Kannel
WB
Wilson
PW
D'Agostino
RB
Cobb
J
,
Sudden coronary death in women
Am Heart J
,
1998
, vol.
136
(pg.
205
-
12
)
25
Albert
CM
Chae
CU
Grodstein
F
Rose
LM
Rexrode
KM
Ruskin
JN
et al.
,
Prospective study of sudden cardiac death among women in the United States
Circulation
,
2003
, vol.
107
(pg.
2096
-
101
)
26
Solomon
SD
Zelenkofske
S
McMurray
JJV
Finn
PV
Velazquez
E
Ertl
G
et al.
,
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
N Engl J Med
,
2005
, vol.
352
(pg.
2581
-
8
)
27
Adabag
AS
Therneau
TM
Gersh
BJ
Weston
SA
Roger
VL
,
Sudden death after myocardial infarction
JAMA
,
2008
, vol.
300
(pg.
2022
-
9
)
28
Ford
ES
Ajani
UA
Croft
JB
Critchley
JA
Labarthe
DR
Kottke
TE
et al.
,
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
N Engl J Med
,
2007
, vol.
356
(pg.
2388
-
98
)
29
Fox
CS
Evans
JC
Larson
MG
Kannel
WB
Levy
D
,
Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study
Circulation
,
2004
, vol.
110
(pg.
522
-
7
)
30
Deo
R
Lin
F
Vittinghoff
E
Tseng
ZH
Hulley
SB
Shlipak
MG
,
Kidney dysfunction and sudden cardiac death among women with coronary heart disease
Hypertension
,
2008
, vol.
51
(pg.
1578
-
82
)
31
Vlietstra
RE
Kronmal
RA
Oberman
A
Frye
RL
Killip
T
3rd
,
Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. Report from the CASS registry
JAMA
,
1986
, vol.
255
(pg.
1023
-
7
)
32
Stecker
EC
Vickers
C
Waltz
J
Socoteanu
C
John
BT
Mariani
R
et al.
,
Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study
J Am Coll Cardiol
,
2006
, vol.
47
(pg.
1161
-
6
)

Supplementary data